Skip to main content

Advertisement

SpringerLink
Log in

In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients

  • Original Contribution
  • Published:
European Journal of Nutrition Aims and scope Submit manuscript

Abstract

Background

Disease preventing effects gained by garlic consumption have been recognized since early period of history, making commercially available garlic supplements attractive to the general public. Possible pharmacokinetic interactions which could occur between applied drugs and aged garlic extract (AGE) are unknown.

Aim

To test in vitro impact of some garlic phytochemicals on P-glycoprotein (Pgp), the most recognized efflux transporter, and the effect of AGE on passive membrane permeability, absorptive and secretory intestinal transporters.

Methods

Rat small intestine and Caco-2 cell monolayers, mounted in side-by-side diffusion chambers were used.

Results

Hydrophilic sulphur compounds increased Pgp mediated Rhodamine 123 (Rho123) efflux, whereas the lipophilic ones increased Pgp efflux through rat ileum but not through Caco-2 cell monolayers. Increased activities of secretory (Pgp, multidrug-resistance associated protein 2) and absorptive (monocarboxylate transporter 1, organic anion transporting polypeptide) transporters involved in drug absorption were observed in rat small intestine and Caco-2 cell monolayers in the presence of AGE. Transport of drugs mediated by breast cancer resistance protein and H+-oligopeptide transporter 1 was activated in rat intestine but inhibited through Caco-2 cells. Passive membrane permeability of tested compounds remained unaltered through rat small intestine, while significant changes were observed with Caco-2 cell monolayers.

Conclusions

Due to the observed in vitro pharmacokinetic interactions between AGE and investigated cardiovascular, antidiabetic and antiviral drugs, in vivo absorption changes are possible, but the magnitude of change depends on the most profound process involved (influx, efflux, passive diffusion) in compounds permeability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rivlin RS (2001) Historical perspective on the use of garlic. J Nutr 131(3S):951S–954S

    CAS  Google Scholar 

  2. Agarwal KC (1996) Therapeutic actions of garlic constituents. Med Res Rev 16:111–124

    Article  CAS  Google Scholar 

  3. Ejaz S, Woong LC, Ejaz A (2003) Extract of garlic (Allium Sativum) in cancer chemoprevention. Exp Oncol 25:93–97

    CAS  Google Scholar 

  4. Yeh YY, Liu L (2001) Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr 131(3S):989S–993S

    CAS  Google Scholar 

  5. Amagase H (2006) Clarifying the real bioactive constituents of garlic. J Nutr 136:716S–725S

    CAS  Google Scholar 

  6. Fugh-Berman A (2000) Herb-drug interactions. Lancet 355:134–138

    Article  CAS  Google Scholar 

  7. Wu CY, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutical drug disposition classification system. Pharm Res 22:11–23

    Article  CAS  Google Scholar 

  8. Deferme S, Augustijns P (2003) The effect of food components on the absorption of Pgp substrates: a review. J Pharm Pharmacol 55:153–162

    Article  CAS  Google Scholar 

  9. Foster B, Foster M, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci 4:176–184

    CAS  Google Scholar 

  10. Lancaster JE, Boland MJ (1989) Flavor Biochem. In: Brewster JL, Rabinowitch HD (eds) Onions and allied crops: food science and minor crops. CRC Press, USA, pp 34–54

    Google Scholar 

  11. Jones MG, Hughes J, Tregova A, Milne J, Tomsett AB, Collin HA (2004) Biosynthesis of the flavour precursors of onion and garlic. J Exp Bot 55:1903–1918

    Article  CAS  Google Scholar 

  12. Holub BJ, Arnott K, Davis JP, Nagpurkar A, Peschell J (2002) Organosulfur compounds from garlic. In: Shi J, Mazza G, Maguer M (eds) Functional foods, biochemical and processing aspects. CRC Press, USA, pp 214–231

    Google Scholar 

  13. Berginc K, Uršič D, Žakelj S, Kristl A (2009) Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull 32:694–699

    Article  CAS  Google Scholar 

  14. Rosen RT, Hiserodt RD, Fukuda EK, Ruiz RJ, Zhou Z, Lech J, Rosen SL, Hartman TG (2001) Determination of allicin, S-allylcysteine and volatile metabolites of garlic in breath, plasma or simulated gastric fluids. J Nutr 131(3S):968S–971S

    CAS  Google Scholar 

  15. Amagase H, Petesch BL, Matsuura H, Kasuga S (2001) Intake of garlic and its bioactive components. J Nutr 131(S3):955S–962S

    CAS  Google Scholar 

  16. Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130–137

    Article  CAS  Google Scholar 

  17. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203–1211

    Article  CAS  Google Scholar 

  18. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I (2002) Rate-limiting steps of human oral absorption and QSAR studies. Pharm Res 19:1446–1457

    Article  CAS  Google Scholar 

  19. Su SF, Huang JD (1996) Inhibition of intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 24:142–147

    CAS  Google Scholar 

  20. Soldner A, Benet LZ, Mutschler E, Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 129:1235–1243

    Article  CAS  Google Scholar 

  21. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptors in humans. Drug Metab Dispos 34:1247–1254

    Article  CAS  Google Scholar 

  22. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760–768

    CAS  Google Scholar 

  23. Wang E, Casciano CN, Clement RP, Johnson WW (2001) HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 18:800–806

    Article  CAS  Google Scholar 

  24. Varma MVS, Sateesh K, Panchagnula R (2004) Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2:12–21

    Article  Google Scholar 

  25. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KLR (2006) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulphate in the rat. JPET 319:459–467

    Article  CAS  Google Scholar 

  26. Žakelj S, Šturm K, Kristl A (2006) Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int J Pharm 313:175–180

    Article  Google Scholar 

  27. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products — general considerations. Food and Drug Administration, Center for Drug evaluation and Research (CDER). Available via DIALOG http://www.fda.gov/cder/guidance/index.htm

  28. Maclean C, Moenning U, Reichel A, Fricker G (2008) Closing the gaps–A full scan of the intestinal expression of Pgp, Bcrp and Mrp2 in male and female rats. Drug Metab Dispos 36:1249–1254

    Article  CAS  Google Scholar 

  29. Lee E, Ryan S, Birmingam B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330–341

    Article  CAS  Google Scholar 

  30. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S (2004) Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci 21:3–16

    Article  CAS  Google Scholar 

  31. Faria TN, Timoszyk JK, Stouch TR, Vig BS, Landowski CP, Amidon GL, Weaver CD, Wall DA, Smith RL (2003) A novel high-throughput Pept1 transporter assay differentiates between substrates and antagonists. Mol Pharm 1:67–76

    Article  Google Scholar 

  32. Kivistö KT, Niemi M (2007) Influence of drug transporter polimorphism on pravastatin pharmacokinetics in humans. Pharm Res 24:239–247

    Article  Google Scholar 

  33. Katsura T, Inui KI (2003) Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab Pharmacokinet 18:1–15

    Article  CAS  Google Scholar 

  34. Sha X, Yan G, Wu Y, Li J, Fang X (2005) Effect of self-emulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 24:477–486

    Article  CAS  Google Scholar 

  35. Rahman K, Lowe GM (2006) Garlic and cardiovascular disease: a critical review. J Nutr 136(3):736S–740S

    CAS  Google Scholar 

  36. Flesch G, Muller PL (1997) Absolute bioavailability and pharmacokinetics of valsaratn, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:115–120

    Article  CAS  Google Scholar 

  37. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek C, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641–649

    Article  CAS  Google Scholar 

  38. Ebert B, Seidel A, Lampen A (2005) Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754–1763

    Article  CAS  Google Scholar 

  39. Heimeur A, Conseil G, Deeley RG, Cole SPC (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Current drug metabolism 5:21–53

    Article  Google Scholar 

  40. Huang L, Wang Y, Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738–743

    Article  CAS  Google Scholar 

  41. Masereel B, Pochet L, Laeckmann D (2003) An overview of inhibitors of Na/H exchanger. Eur J Med Chem 38:547–554

    Article  CAS  Google Scholar 

  42. Anderle P, Huang Y, Sadee W (2004) Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. Eur J Pharm Sci 21:17–24

    Article  CAS  Google Scholar 

  43. Gupta N, Martin PM, Miyauchi S, Ananth S, Herdman AV, Martindale RG, Podolsky R, Ganapathy V (2006) Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. BBRC 343:571–577

    CAS  Google Scholar 

  44. Shin HS, Bae SK, Lee MG (2006) Pharmacokinetics of sildenafil after intravenous and oral administration of rats: hepatic and intestinal first-pass effects. Int J Pharm 320:64–70

    Article  CAS  Google Scholar 

  45. Halestrap AP, Meredith D (2004) The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 447(5):619–628

    Article  CAS  Google Scholar 

  46. Gill RK, Saksena S, Alrefai WA, Sarwar Z, Goldstein JL, Carroll RE, Ramaswamy K, Dudeja PK (2005) Expression and membrane localization of MCT isoforms along the length of human intestine. Am J Physiol Cell Physiol 289:C846–C852

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, p.p. 311, 1000, Ljubljana, Slovenia

    Katja Berginc, Simon Žakelj & Albin Kristl

Authors
  1. Katja Berginc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon Žakelj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albin Kristl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katja Berginc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berginc, K., Žakelj, S. & Kristl, A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr 49, 373–384 (2010). https://doi.org/10.1007/s00394-010-0095-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00394-010-0095-x

Keywords

Search

Navigation